End-payors for Amitiza seek class certification in US antitrust case against Takeda (corrects*)
MLex Summary: End-payors for the drug Amitiza* asked a US federal judge to certify a proposed class in litigation accusing Takeda Pharmaceuticals of delaying a generic competitor. If approved, the class...To view the full article, register now.
Already a subscriber? Click here to view full article